#AAIC2026 is an active hashtag on Bluesky. In the last 30 days, 55 people shared 96 posts with it — around 3 a day. Activity is down 17% versus the previous week, peaking on Jul 13 with 17 posts.
Tags most often used together with #AAIC2026.
bit.ly
Tau Protein Blood Tests and More From AAIC 2026
This Medical News article is an interview with neurologist Gil Rabinovici, MD, about research presented at the recent Alzheimer’s Association International Conference in London.
bit.ly
Tau Protein Blood Tests and More From AAIC 2026
This Medical News article is an interview with neurologist Gil Rabinovici, MD, about research presented at the recent Alzheimer’s Association International Conference in London.
JAMA @jama.com
#MedNews: Blood tests for p-tau217, brain changes in former elite soccer players, and culturally tailored lifestyle interventions were among the highlights from #AAIC2026.
jamanetwork.com
jamanetwork.com
Tau Protein Blood Tests and More From AAIC 2026
This Medical News article is an interview with neurologist Gil Rabinovici, MD, about research presented at the recent Alzheimer’s Association International Conference in London.
www.neurologylive.com
IBC-Ab002 Shows Favorable Safety Profile, Exploratory Biomarker Signals in Alzheimer Disease Trial | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investig...
www.springermedicine.com
Anti-tau treatment ceperognastat fails to slow early AD progression
Inhibition of O-linked N-acetylglucosaminidase with ceperognastat does not slow progression of early Alzheimer disease compared with placebo.
www.springermedicine.com
Centiloid thresholds for amyloid PET positivity in Alzheimer disease defined
Researchers have identified amyloid PET positivity thresholds to be around 18 to 27 Centiloids, based on a combination of data-driven methods and visual reads.
dlvr.it
Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial - Nature Medicine
A phase 1b trial shows that IBC-Ab002, a short-lived antibody that intermittently activates the peripheral immune system, is safe and well tolerated with trends in biomarkers in people with early Alzheimer’s disease, supporting further clinical development.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
